Analytical Data
-
Gene name
MID1
- Application
-
Alternative Names
BBBG1; Midin; FXY; GBBB1; OGS1; OS; OSX; RNF59; TRIM18; XPRF; ZNFXY; Opitz/BBB Syndrome; RING finger protein 59; Tripartite motif-containing protein 18
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O70583
-
Expression Region
Met1~Leu212
-
Molecular Weight
28kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MID1 is a protein that plays a crucial role in various cellular processes, particularly in the regulation of cell growth and division. It is a member of the MID (Midline-1) protein family and has garnered attention due to its involvement in specific pathological conditions, including the development of certain cancers and genetic disorders such as Opitz syndrome. Research into MID1 has revealed its function as an E3 ubiquitin ligase, which mediates protein degradation and stability, thereby influencing key signaling pathways. The dysregulation of MID1 activity has been linked to abnormal cellular proliferation and apoptosis, making it a potential target for therapeutic interventions. Recent studies have focused on understanding the molecular mechanisms underlying MID1 function, its role in tumorigenesis, and the implications of its aberrant expression. Consequently, the development of MID1 recombinant proteins has become a vital area of research, aiming to facilitate the exploration of its biological functions and to investigate potential pharmacological strategies to modulate its activity in disease contexts. This research not only enhances our understanding of MID1's role in cell biology but also opens up new avenues for targeted therapies in cancers and genetic disorders associated with MID1 dysfunction.
